Autoimmunity roots of the thrombotic events after COVID-19 vaccination.

Abstract

Although vaccination represents the most promising way to stop or contain the coronavirus disease 2019 (COVID-19) pandemic and safety and effectiveness of available vaccines were proven, a small number of individuals who received anti-SARS-CoV-2 vaccines developed a prothrombotic syndrome. Vaccine-induced immune thrombotic thrombocytopenia (VITT) can be triggered by the adenoviral vector-based vaccine, whereas lipid nanoparticle-mRNA-based vaccines can induce rare cases of deep vein thrombosis (DVT). Although the main pathogenic mechanisms behind this rare phenomenon have not yet been identified, both host and vaccine factors might be involved, with pathology at least in part being related to the vaccine-triggered autoimmune reaction. In this review, we are considering some aspects related to pathogenesis, major risk factors, as well as peculiarities of diagnosis and treatment of this rare condition.

• Authors: Fatma Elrashdy, Murtaza M Tambuwala, Sk Sarif Hassan, Parise Adadi, Murat Seyran, Tarek Mohamed Abd El-Aziz, Nima Rezaei, Amos Lal, Alaa A A Aljabali, Ramesh Kandimalla, Nicolas G Bazan, Gajendra Kumar Azad, Samendra P Sherchan, Pabitra Pal Choudhury, Ángel Serrano-Aroca, Kazuo Takayama, Gaurav Chauhan, Damiano Pizzol, Debmalya Barh, Pritam Kumar Panda, Yogendra K Mishra, Giorgio Palù, Kenneth Lundstrom, Elrashdy M Redwan, Vladimir N Uversky
• Journal: Autoimmunity reviews (Autoimmun Rev) Vol. 20 Issue 11 Pg. 102941 (Nov 2021) ISSN: 1873-0183 [Electronic] Netherlands
• PMID: 34508917 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2021 Elsevier B.V. All rights reserved.

Chemical References

• COVID-19 Vaccines
• Viral Vaccines

Topics

• Autoimmunity
• COVID-19
• COVID-19 Vaccines
• Humans
• Severe acute respiratory syndrome-related coronavirus
• SARS-CoV-2
• Vaccination (adverse effects)
• Viral Vaccines